• Institute of Good Manufacturing Practices India
  • Global accredited training & certification provider
  • Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India
  • Approved Training Institute of Food Safety and Standards Authority of India (FSSAI)
  • Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India
  • An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India
  • Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh
  • Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC) set up by National Skill Development Corporation (NSDC)
  • Conferred with QUALITY COUNCIL OF INDIA (QCI) – D.L. SHAH NATIONAL QUALITY AWARD & ASSOCHAM Services Excellence Award 2017

Trusted by organizations & training participants in over 30 countries
Training | Certification | Education | Research


Updated: Dec 06, 2018

As per the reports, during an inspection of US vascular's medical device manufacturing facility at Beaverton by US FDA, there have been 11 contraventions of good manufacturing practices, as per a FDA warning letter.

The inspection of the new manufacturing facility of Biocon was completed by USFDA without any findings. In a Regulatory filing, Biocon said "A pre-compliance investigation was conducted for our new manufacturing facility of oral solid dosage forms at Biocon Park in Bengaluru was conducted by The United States food and drug administration (USFDA) from November 5-9 2018".

The inspection was finished without any observation and Form 483 was not issued. Form 483 is issued by USFDA to inform to inform the management of the company of any unacceptable condition at its manufacturing facility. After completion of the inspection, the form is issued.

Biocon's shares were trading .27 percent lower at 638.70 apiece on the BSE.